The Honest Dose #10

The emails I get have been changing, and it's telling me something.

When I started this, I pictured the average reader as someone standing at the very front of the funnel: curious, cautious, trying to figure out whether any of this peptide stuff is real before going near it. A lot of you are exactly that, and I love those emails. But a growing share of what lands in my inbox is coming from further down the road. People who are past the "is this legitimate" question and are now deep in the "how do I not get ripped off" question. They're not asking whether a compound has evidence. They're asking how to tell whether the thing showing up at their door is what the label says it is.

That's a different problem, and right now it's one I haven't built anything for.

So here's where I'm pointing next. The same way the Research Quality Score grades the evidence behind a compound, I want to build an honest, transparent way to grade the process behind a vendor. Not endorsements. Not "trusted seller" badges that quietly track who's paying. A score built only on things you can actually verify from the outside: how often a vendor does third-party testing, whether their lab results are public, whether you can trace a specific batch, what their reship and refund terms actually say. Objective inputs, published openly, the same principle that makes the RQS worth reading.

I'm not putting a date on it yet, and I'm not naming any vendors today. Before I grade anyone, the framework has to be airtight, because the entire reason this newsletter is worth your time is that I don't have a thumb on the scale. But it's the direction, and today's lead compound is a preview of exactly why it matters.

Let's get into it.

Pentadeca Arginate, sold everywhere as "PDA," is a 15-amino-acid peptide marketed as the next-generation upgrade to BPC-157. The pitch is consistent across every vendor page you'll find: same healing properties as BPC-157, but more stable, better absorbed, and more effective, thanks to swapping the usual acetate salt for an arginate one.

It's a good pitch. It's also, at the level of published human evidence, almost entirely unsupported.

Here's the part the marketing skips. The actual peptide sequence in PDA is the same sequence as BPC-157. The "arginate" refers to the counterion it's paired with, essentially a different salt form, not a different molecule. So when a vendor tells you PDA is a structurally superior compound, what they're mostly describing is a change in how the peptide is packaged, not a redesign of the peptide itself.

And the timing tells you why it exists at all. PDA showed up in force right as the FDA moved against BPC-157 in compounding. A compound facing regulatory pressure suddenly had a close cousin with a new name and no regulatory history of its own. That is not a coincidence. It's a workaround.

This is the shortest "science" section I've written, and that's the entire point.

There are no published human trials of pentadeca arginate as a distinct molecule. Not thin ones. Not preliminary ones. None. The claims of superiority over BPC-157 rest on mechanistic reasoning about arginine and nitric oxide, plus the assumption that PDA inherits whatever BPC-157 has going for it.

The problem with inheriting BPC-157's evidence is that BPC-157's evidence is itself almost entirely from animal models, with no human RCT data of its own. So PDA is asking you to accept a borrowed evidence base that was already weak in the compound it was borrowed from, and then to accept an unproven claim that the new salt form makes it better still. That's two speculative leaps stacked on top of each other, sold as an upgrade.

None of this means PDA does nothing. It means nobody has actually shown what it does in humans, in a controlled setting, with the molecule itself as the thing under study. Absence of evidence is not evidence of absence. But it is absence of evidence, and when a compound is being actively marketed as superior, the burden sits with the people making that claim to produce the trials. They haven't.

PDA is one of the clearest cases in the entire catalog of a compound whose market presence dramatically outruns its research. It's a salt-form variant of an animal-data-only peptide, given a new name at the exact moment its predecessor drew regulatory heat, and sold as a scientific advance it has never been tested to support. The story of PDA is not a story about biology. It's a story about how compounds get named, sold, and positioned, which is precisely the territory a vendor transparency framework is built to cover.

RQS: 19/100 - Insufficient Evidence

Read the full Pentadeca Arginate profile

The claim: You're stuffed up on the couch, and someone tells you to go get some fresh air, it'll do you good. It's one of those pieces of folk wisdom that's so old it feels self-evidently true. Its equally popular twin is the opposite instruction: don't go out in that cold, you'll make it worse. Both can't be right, and it turns out the truth is more interesting than either.

The reality: Start with what's flatly false. Cold air does not cause a cold. You cannot catch a viral infection from weather. You catch it from a virus, and if there's no rhinovirus or coronavirus present, you can stand in the wind all day and stay perfectly healthy. That part of grandma's warning doesn't hold.

But there's a genuine mechanism hiding underneath it. A 2022 study published in the Journal of Allergy and Clinical Immunology gave the first solid biological explanation for why respiratory infections spike in the cold. The researchers found that the front of your nose runs a frontline antiviral defense: it releases swarms of tiny extracellular vesicles that intercept inhaled viruses before they can infect your cells. When they exposed volunteers to roughly 40°F air for fifteen minutes, the temperature inside the nose dropped by about 5°C, and that small drop cut the output of those protective vesicles by more than 40 percent, along with a steep drop in the virus-neutralizing machinery each one carried. In other words, cold air doesn't create the virus, but it does measurably lower the defenses at the exact spot the virus enters. So the "bundle up" instinct has a real basis, just not the one people think.

Now the other half. Does going outside help you recover faster once you're already sick? Here the honest answer is that there's no good clinical evidence that fresh air speeds up recovery from a cold. The benefits people report are real but indirect: getting out of a closed room reduces how much you re-breathe concentrated indoor air, moving around and daylight tend to lift mood, and none of it makes a cold worse if you're dressed for the weather and the illness is above the neck. What fresh air is not is a treatment. It won't shorten the virus.

The honest version of the claim: Cold weather doesn't give you a cold, but being cold genuinely blunts your nose's first line of defense, which is a real reason infections cluster in winter. And once you already have a cold, fresh air is fine and might make you feel better, but it isn't medicine and won't get you well any faster. The comforting walk outside is worth taking. Just don't expect it to do a job that only your immune system and time can actually do.

This is a general-health topic, not peptide-specific, and nothing here is medical advice. If you're sick enough to be wondering whether something's wrong, that's a question for a clinician, not a newsletter.

A 19 is one of the lowest scores in the catalog, and it's worth being precise about why, because "low score" and "bad compound" are not the same statement, and the difference is the whole philosophy of the RQS.

PDA scores at the floor for a specific, structural reason: there is essentially nothing to grade. The RQS rewards study design, replication, funding independence, and the strength of human outcome data. PDA has no human trials of its own to assess on any of those dimensions. You cannot score the quality of research that doesn't exist. What little can be evaluated is inherited from BPC-157, and that borrowed base is animal-model data, which caps how high any score built on it can climb.

Compare this to a compound like DSIP, which I covered in Issue 8 and which also sits low. DSIP at least has decades of direct study, a small human signal, and a real if incomplete literature to weigh. PDA doesn't have that. It's newer, thinner, and defined more by its marketing position than by any body of work. That's the difference between a compound that's been studied and found wanting, and one that simply hasn't been studied at all.

The score is not a verdict on whether PDA is safe or whether it works. It's a measurement of how much trustworthy evidence stands behind the claims being made about it. Right now that measurement reads close to empty, and the honest thing to do is show you the empty gauge rather than dress it up.

Today's lead is a preview of a whole category worth watching.
PDA isn't a one-off. It's an example of a pattern: compounds that exist primarily as regulatory arbitrage, engineered or renamed to sidestep pressure on a more established substance. When the science barely changes but the name and the salt form do, you're looking at a sourcing-and-marketing maneuver wearing a lab coat. This is precisely the gap a vendor transparency framework is meant to close, because the question stops being "what does the research say" and becomes "who is selling this, what are they testing, and what are they actually telling you." Expect me to keep flagging these as they appear.

The FDA's peptide compounding meeting is now days away.
The Pharmacy Compounding Advisory Committee meets July 23-24 to evaluate seven peptides for the 503A Bulk Drug Substances list: BPC-157, KPV, TB-500, and MOTS-c on day one, then DSIP, Semax, and Epitalon on day two. Two things stand out heading in. First, the FDA has already posted its own scientific briefing documents, and for all seven, the agency's position is the same: propose not to add them to the list. Notably, the briefings cover both the free base and acetate salt forms of each substance, which is exactly the kind of salt-form distinction PDA relies on to exist as a separate product. Second, the framing in those briefings is fundamentally an evidence argument, not a safety ban, which lands squarely on what the RQS has been measuring all along. Keep the process in perspective, though: the committee's vote is advisory and non-binding, and even a favorable recommendation would still require a formal rulemaking process that typically runs well over a year. This is a milestone, not a finish line. I'll report back once the meeting produces something concrete.

Where we're headed next issue.
With summer in full swing, I'm making the next lead one of the most searched and least honestly discussed compounds in the whole space: Melanotan II, the so-called tanning peptide. It's a compound with a genuinely fascinating twist, its development was abandoned before the finish line, and yet one of its direct descendants went on to earn FDA approval. If you've ever wondered how a grey-market research chemical and an approved prescription drug can share the same origin story, that's the thread we'll pull next time.

You can't tell the PDA story without its predecessor, so BPC-157 is the natural companion this issue.

BPC-157, nicknamed "Wolverine" in the community for its reputation around healing, is a synthetic peptide derived from a protein found in gastric juice. In animal models it shows genuinely striking results across tendon repair, gut lining recovery, and anti-inflammatory effects, and that animal data is real and reasonably extensive. It's one of the most widely used compounds in the entire recovery-and-performance space.

The catch is the one that matters most: there is no human RCT data. Everything driving the enthusiasm is preclinical, and as I covered back in Issue 5, the funding picture around the compound's core research carries a documented conflict that further complicates how much confidence the evidence can bear. BPC-157 scores a 20, one point above PDA, and that single point is instructive. BPC-157 at least has a deep, direct animal literature under study. PDA borrows that same literature, adds an untested superiority claim, and arrives with a newer name and less of its own. The parent compound is thinly evidenced in humans. The "upgrade" is thinner still.

RQS: 20/100 - Weak Evidence

Read the full BPC-157 profile

Hopefully that was helpful/interesting, see you next week.

-Emeka

Peptidclear.com

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.